ICH Guidance Urges Use of Risk Assessments for CQAs

Drugmakers should use risk assessments to identify material attributes and manufacturing process parameters that may affect a drug’s critical quality attributes (CQAs), a draft International Conference on Harmonisation (ICH) guidance says.
Washington Drug Letter